SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) — SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA) for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, for the treatment of glioblastoma multiforme (GBM). The FDA’s Office of Orphan Products Development (OOPD) has formally acknowledged receipt of the request and is proceeding with review on additional files about the product

QTREX Establishes U.S. Subsidiary to Advance Federal Government Contracting

Ness Ziona, Israel, July 10, 2026 (GLOBE NEWSWIRE) — QTREX Quantum Ltd. (Nasdaq: QTEX) (“QTREX” or the “Company”) a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure today announced the formation of QTREX USA, its new U.S. subsidiary serving as the Company’s dedicated platform for U.S. federal contract execution. The move follows QTREX’s recently announced operational AME deployment at a U.S. government laboratory conducting quantum computing programs, and is intended to support the Company’s federal government contracting activities in the United States.

Branzy Advances Economic Independence through Public Welfare Initiatives and Digital Literacy Training in Mozambique

NEW YORK, NY, July 10, 2026 (GLOBE NEWSWIRE) — Digital promotion leader Branzy (https://www.branzy.top) has officially launched a comprehensive series of public welfare activities and offline specialized training programs aimed at empowering local communities and driving job creation. This initiative comes as part of a landmark five-year cooperation agreement signed between Branzy and the relevant authorities in Mozambique.

BMGL Regains Compliance With Nasdaq Minimum Bid Price Requirement

Singapore, July 10, 2026 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that the Company has regained compliance with the Nasdaq minimum bid price rule. On January 22, 2026, Nasdaq notified the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Nasdaq has determined that for the last 10 consecutive business days, from June 23, 2026 to July 7, 2026, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).

Global Power Solutions Announces Registration to Attend Data Centre West 2026 in Calgary and Applauds Meta’s Historic CAD $13 Billion Alberta Data Centre Investment

Vancouver, BC, Canada, July 10, 2026 (GLOBE NEWSWIRE) — Global Power Solutions Corp. (TSX Venture Exchange: PWER; Frankfurt Stock Exchanges: NJA) (“Global Power” or the “Company”) is pleased to announce that the Company has registered and will be in attendance at the Data Centre West 2026 (“Data Centre West”) conference, taking place September 9, 2026 at the Hyatt Regency in downtown Calgary, Alberta.